• Elizabeth Jordan, Daniel D Kinnamon, Garrie J Haas, Mark Hofmeyer, Evan Kransdorf, Gregory A Ewald, Alanna A Morris, Anjali Owens, Brian Lowes, Douglas Stoller, TangW H WilsonWHWCleveland Clinic, Cleveland, Ohio., Sonia Garg, Barry H Trachtenberg, Palak Shah, Salpy V Pamboukian, Nancy K Sweitzer, Matthew T Wheeler, Jane E Wilcox, Stuart Katz, Stephen Pan, Javier Jimenez, Daniel P Fishbein, Frank Smart, Jessica Wang, Stephen S Gottlieb, Daniel P Judge, Charles K Moore, Jonathan O Mead, Natalie Hurst, Jinwen Cao, Gordon S Huggins, Jason Cowan, Hanyu Ni, Heidi L Rehm, Gail P Jarvik, Matteo Vatta, Wylie Burke, Ray E Hershberger, and DCM Precision Medicine Study of the DCM Consortium.
• Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus.
• JAMA. 2023 Aug 1; 330 (5): 432441432-441.

ImportanceBlack patients with dilated cardiomyopathy (DCM) have increased familial risk and worse outcomes than White patients, but most DCM genetic data are from White patients.ObjectiveTo compare the rare variant genetic architecture of DCM by genomic ancestry within a diverse population of patients with DCM.DesignCross-sectional study enrolling patients with DCM who self-identified as non-Hispanic Black, Hispanic, or non-Hispanic White from June 7, 2016, to March 15, 2020, at 25 US advanced heart failure programs. Variants in 36 DCM genes were adjudicated as pathogenic, likely pathogenic, or of uncertain significance.ExposurePresence of DCM.Main Outcomes And MeasuresVariants in DCM genes classified as pathogenic/likely pathogenic/uncertain significance and clinically actionable (pathogenic/likely pathogenic).ResultsA total of 505, 667, and 26 patients with DCM of predominantly African, European, or Native American genomic ancestry, respectively, were included. Compared with patients of European ancestry, a lower percentage of patients of African ancestry had clinically actionable variants (8.2% [95% CI, 5.2%-11.1%] vs 25.5% [95% CI, 21.3%-29.6%]), reflecting the lower odds of a clinically actionable variant for those with any pathogenic variant/likely pathogenic variant/variant of uncertain significance (odds ratio, 0.25 [95% CI, 0.17-0.37]). On average, patients of African ancestry had fewer clinically actionable variants in TTN (difference, -0.09 [95% CI, -0.14 to -0.05]) and other genes with predicted loss of function as a disease-causing mechanism (difference, -0.06 [95% CI, -0.11 to -0.02]). However, the number of pathogenic variants/likely pathogenic variants/variants of uncertain significance was more comparable between ancestry groups (difference, -0.07 [95% CI, -0.22 to 0.09]) due to a larger number of non-TTN non-predicted loss of function variants of uncertain significance, mostly missense, in patients of African ancestry (difference, 0.15 [95% CI, 0.00-0.30]). Published clinical case-based evidence supporting pathogenicity was less available for variants found only in patients of African ancestry (P < .001).Conclusion And RelevancePatients of African ancestry with DCM were less likely to have clinically actionable variants in DCM genes than those of European ancestry due to differences in genetic architecture and a lack of representation of African ancestry in clinical data sets.

22 keywords...

hide…